Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients-Reference-Cited by-同舟云学术

Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients

Published:2010-02-25 Issue:7 Volume:29 Page:1248-1261
ISSN:0261-4189
Container-title:The EMBO Journal
language:
Short-container-title:EMBO J

Author:

Sellier Chantal,Rau Frédérique,Liu Yilei,Tassone Flora,Hukema Renate K,Gattoni Renata,Schneider Anne,Richard Stéphane,Willemsen Rob,Elliott David J,Hagerman Paul J,Charlet-Berguerand Nicolas

Publisher

Springer Science and Business Media LLC

Reference50 articles.

1. Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3β

2. An Optimized MALDI Mass Spectrometry Method for Improved Detection of Lysine/Arginine/Histidine Free Peptides

3. Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells

4. CGG‐repeat length and neuropathological and molecular correlates in a mouse model for fragile X‐associated tremor/ataxia syndrome

5. Sam68 Regulates a Set of Alternatively Spliced Exons during Neurogenesis

Cited by 322 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fluorescent RNAs: new opportunities for drug discovery;Trends in Pharmacological Sciences;2025-06

2. Insufficiency of 40S ribosomal proteins, RPS26 and RPS25, negatively affects biosynthesis of polyglycine-containing proteins in fragile-X associated conditions;eLife;2025-05-16

3. Insufficiency of 40S ribosomal proteins, RPS26 and RPS25, negatively affects biosynthesis of polyglycine-containing proteins in fragile-X associated conditions;eLife;2025-05-16

4. Involvement of the Cerebellar Peduncles in FMR1 Premutation Carriers: A Pictorial Review of Their Anatomy, Imaging, and Pathology;International Journal of Molecular Sciences;2025-05-06

5. Epigenetics Modulators as Therapeutics for Neurological Disorders;Current Pharmaceutical Design;2025-05